Gynaecological Malignancies in Nigeria: A Systematic Review
Published: 2022-12-14
Page: 168-186
Issue: 2022 - Volume 5 [Issue 2]
Angela Chinasa Ani
University of Nigeria Teaching Hospital, Enugu, Nigeria.
Chika Augusta Ekweozor *
University of Nigeria Teaching Hospital, Enugu, Nigeria.
Marydith Ifeoma Chukwu
Federal Medical Centre, Lokoja, Nigeria.
Chioma Jacinta Chukwueloka
National Hospital, Abuja, Nigeria.
*Author to whom correspondence should be addressed.
Abstract
Introduction: Gynaecological malignancies cause most death in women. The estimation of gynaecological epidemiology is invaluable in setting priorities for its control. No study has elucidated the epidemiological burden on Nigerian women until this point.
Methods: Our work covered published articles on gynaecological malignancies in Nigeria. The terms of search are "Gynaecological malignancies" and "Nigeria". We searched databases (PubMed, AJOL, Research4Life, Science Direct, Scopus, and Google Scholar), journal homepages (BMC, Sahel Medical Journal), and free web searches of related papers. Downloaded papers were assessed for eligibility following PRISMA 2009.
Results: The charted data indicated that cervical, ovarian, and uterine were the commonest forms. The rarest was fallopian tube cancers. Developed cities in Nigeria, such as Lagos, Zaria, Anambra, and Enugu had the highest number of publications. In contrast, less developed states such as Imo, Lokoja, Oyo, Akwa Ibom, Bauchi, Benin, Delta, Kebbi and Ogun states had the least publications. The histological screening was the primary means of diagnosis. Risk factors for some reported cases include active sexual history, age, parity, and family history.
Conclusions: The distribution pattern of gynaecological cancers is consistent with what is obtainable worldwide, where cervical, ovarian, and uterine cancers were identified as the most prevalent.
National screening protocol, national health insurance schemes, and workforce education are key to early detection, mitigating diseases, and improving survival outcomes.
Keywords: Gynaecological malignancies, cancers, burden, epidemiology, systematic review, prevalence, incidence
How to Cite
Downloads
References
Levine R, Krenning EP. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: Historical review based on an interview of eric p. krenning by rachel levine. The Journal of Nuclear Medicine. 2017;58(2):2.
Marin JG, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Felipe G. Barbosa FG, Queiroz MA, Cerri GG, Buchpiguel CA. Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. Radio Graphics. 2020;40:1715–1740.
Vecchio SD, Zannetti A, Fonti R, Pace L, Salvatore M. Nuclear imaging in cancer theranostics. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2007;51(2):152-163.
Chen X, Wong STC. Cancer Theranostics: An Introduction. Chen X. and Wong S. T. C. (ed). Cancer Theranostics. 2014;978-0-12-407722-5.
Ziegler A, Koch A, Krockenberger K, Großhennig A. Personalized medicine using DNA biomarkers: a review. Human Genetics. 2012;131:1627–1638.
Jeevanandam J, Sabbih G, Tan KX, Danquah MK. Oncological ligand-target binding systems and developmental approaches for cancer theranostics. Molecular Biotechnology. 2021;63:167-183.
Bertoli G, Cava C, Castiglioni I. MicroRNAs as biomarkers for diagnosis prognosis and theranostics in prostate cancer. International Journal of Molecular Sciences. 2016;17(421):21.
Filipów S, Łaczmanski L. Blood Circulating miRNAs as Cancer Biomarkers for Diagnosis and Surgical Treatment Response. Frontiers in Genetics. 2019; 10:169.
Panagiotara A, Markou A, Lianidou ES, Patrinos GP, Katsila T. Exosomes: A cancer theranostics road map. Public Health Genomics. 2017;20:116–125.
Arranja AG, Pathak V, Lammers T, Shi Y. Tumor-targeted nanomedicines for cancer theranostics. Pharmacological Research. 2017;115:87–95.
Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Accounts of Chemical Research. 2011;44(10):1105-1113.
Luk BT, Fang RH, Zhang L. Lipid- and Polymer-Based Nanostructures for Cancer Theranostics. Theranostics. 2012;2(12): 1117-1126.
Specht JM, Mankoff DA. Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Research. 2012;14:206.
Cai J, Li F. Single-photon emission computed tomography tracers for predicting and monitoring cancer therapy. Current Pharmaceutical Biotechnology. 2013;14(7):693-707.
Luo S, Zhou T. Superiorization of EM algorithm and its application in Single-Photon Emission Computed Tomography (SPECT). Inverse Problems and Imaging. 2014;8(1):223-246.
Xu S, Shi X, Chu C, Liu G. A TME-activated in situ nanogenerator for magnetic resonance/ fluorescence/ photoacoustic imaging. In J Chan (eds). Methods in Enzymology. Academic Press. 2021;657:145-156.
Valluru KS, Willmann JK. Clinical photoacoustic imaging of cancer. Ultrasonography. 2016;35:267-280.
Mehrmohammadi M, Yoon S.J, Yeager D, Emelianov SY. photoacoustic imaging for cancer detection and staging. Current Molecular Imaging. 2013;2(1):89–105.
Gharieb RR. Photoacoustic imaging for cancer diagnosis: A Breast tumor example. In Gharieb R. R (ed). Photoacoustic imaging - principles advances and applications. Intech Open London; 2020.
DOI:10.5772/intechopen.92084.
Wang X, Yang M. The application of ultrasound image in cancer diagnosis. Journal of Healthcare Engineering. 2021;8.